KRP-AM1977X Phase III Open-label Study (Respiratory Tract Infection)

KRP-AM1977X PhaseIII Clinical Study-Open-label study for the patients with respiratory tract infection-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222861

Enrollment

Registered

2015-05-25

Start date

2015-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary infection of chronic respiratory disease and acute bronchitis

Interventions

investigational material(s) Generic name etc : KRP-AM1977X Tablet INN of investigational material : lascufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Respiratory tract infection with clear infection symptoms

Exclusion criteria

Exclusion criteria: Patient with severe infection Patient with serious functional disorder that would unsuitable for the study Patient showing the tendency to improve pneumonia symptoms by other agents etc

Design outcomes

Primary

Measure	Time frame
efficacy Secondary infection of chronic respiratory disease: Clinical efficacy at test of cure Acute bronchitis: Clinical efficacy at end of treatment Assessment of clinical response by comparing the clinical findings.	—

Secondary

Measure	Time frame
efficacy Secondary infection of chronic respiratory disease: Clinical efficacy at end of treatment, etc. Acute bronchitis: Clinical efficacy at test of cure, etc. Assessment of clinical response by comparing the clinical findings.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026